Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Receivables (2017 - 2025)

Historic Change in Receivables for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to -$6.2 million.

  • Akebia Therapeutics' Change in Receivables fell 35613.31% to -$6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.3 million, marking a year-over-year increase of 27913.97%. This contributed to the annual value of -$4.0 million for FY2024, which is 30704.23% down from last year.
  • Per Akebia Therapeutics' latest filing, its Change in Receivables stood at -$6.2 million for Q3 2025, which was down 35613.31% from $11.5 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Change in Receivables high stood at $27.9 million for Q1 2025, and its period low was -$58.7 million during Q3 2022.
  • Its 5-year average for Change in Receivables is $2.2 million, with a median of $3.1 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Akebia Therapeutics' Change in Receivables was 739956.14% (2022), while the steepest drop was 49995.23% (2022).
  • Over the past 5 years, Akebia Therapeutics' Change in Receivables (Quarter) stood at $1.2 million in 2021, then surged by 1329.83% to $17.0 million in 2022, then fell by 1.86% to $16.7 million in 2023, then tumbled by 81.59% to $3.1 million in 2024, then crashed by 300.39% to -$6.2 million in 2025.
  • Its Change in Receivables was -$6.2 million in Q3 2025, compared to $11.5 million in Q2 2025 and $27.9 million in Q1 2025.